***Background.*** Existing cost-effectiveness analyses comparing linezolid and vancomycin for the treatment of a variety of pneumonias utilize data from trials which are controversial. This study examines the cost-effectiveness of vancomycin vs linezolid in the treatment of nosocomial pneumonias incorporating results from a recent prospective, double-blind, multicenter, controlled trial in adults with methicillin-resistant *Staphylococcus aureus* nosocomial pneumonia.

***Methods.*** A decision analytic model was created examining the cost-effectiveness of utilizing linezolid vs vancomycin for treatment of nosocomial pneumonia from a payer perspective with a lifetime time horizon. Publicly available cost, efficacy, and utility data was used to populate relevant model variables. The primary outcome measure was incremental cost-per quality-adjusted life year (QALY) with secondary analyses on incremental cost-per life saved and the budget impact to the United States healthcare system. A probabilistic sensitivity analysis varied parameters in a hypothetical cohort of 10,000 patients and univariate sensitivity analyses assessed the impact of model uncertainties and robustness of our conclusions.

***Results.*** Results indicated the lifetime cost per QALY increased 3% (\$205,761 vs \$212,138) by utilizing linezolid vs vancomycin for nosocomial pneumonia. The incremental cost per QALY by utilizing linezolid over vancomycin was \$56,917. Our model predicted an incremental cost-per life saved of \$491,106 with linezolid utilization. Vancomycin dominated linezolid in the subset of patients with documented MRSA. The incremental cost of utilizing linezolid as the preferred treatment option if no mortality benefit exists between agents was \$6,378 per patient. Variations in all-cause 60-day mortality rates had the potential to impact results. Results of a Monte Carlo simulation demonstrated linezolid had a 69.9% chance to be cost-effective at our willingness-to-pay threshold.

***Conclusion.*** Empiric utilization of linezolid may be a cost-effective alternative to vancomycin; however, results were highly dependent on outcome data which remains controversial. Results provide a multi-factorial framework to facilitate discussions when evaluating antimicrobial therapy for nosocomial pneumonia.
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